256 related articles for article (PubMed ID: 22080959)
1. Retinal dystrophies and gene therapy.
Sundaram V; Moore AT; Ali RR; Bainbridge JW
Eur J Pediatr; 2012 May; 171(5):757-65. PubMed ID: 22080959
[TBL] [Abstract][Full Text] [Related]
2. Gene supplementation therapy for recessive forms of inherited retinal dystrophies.
Smith AJ; Bainbridge JW; Ali RR
Gene Ther; 2012 Feb; 19(2):154-61. PubMed ID: 22033465
[TBL] [Abstract][Full Text] [Related]
3. An Update on Gene Therapy for Inherited Retinal Dystrophy: Experience in Leber Congenital Amaurosis Clinical Trials.
Chiu W; Lin TY; Chang YC; Isahwan-Ahmad Mulyadi Lai H; Lin SC; Ma C; Yarmishyn AA; Lin SC; Chang KJ; Chou YB; Hsu CC; Lin TC; Chen SJ; Chien Y; Yang YP; Hwang DK
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33926102
[TBL] [Abstract][Full Text] [Related]
4. Splicing-correcting therapeutic approaches for retinal dystrophies: where endogenous gene regulation and specificity matter.
Bacchi N; Casarosa S; Denti MA
Invest Ophthalmol Vis Sci; 2014 May; 55(5):3285-94. PubMed ID: 24867912
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial.
Russell S; Bennett J; Wellman JA; Chung DC; Yu ZF; Tillman A; Wittes J; Pappas J; Elci O; McCague S; Cross D; Marshall KA; Walshire J; Kehoe TL; Reichert H; Davis M; Raffini L; George LA; Hudson FP; Dingfield L; Zhu X; Haller JA; Sohn EH; Mahajan VB; Pfeifer W; Weckmann M; Johnson C; Gewaily D; Drack A; Stone E; Wachtel K; Simonelli F; Leroy BP; Wright JF; High KA; Maguire AM
Lancet; 2017 Aug; 390(10097):849-860. PubMed ID: 28712537
[TBL] [Abstract][Full Text] [Related]
6. [Genetic ocular diseases].
Hamel CP
Rev Prat; 2015 Apr; 65(4):467-70. PubMed ID: 26058181
[TBL] [Abstract][Full Text] [Related]
7. [Gene Replacement Therapy for Inherited Retinal Dystrophies].
Mühlfriedel R; Sothilingam V; Tanimoto N; Seeliger MW
Klin Monbl Augenheilkd; 2017 Mar; 234(3):320-328. PubMed ID: 28355661
[TBL] [Abstract][Full Text] [Related]
8. [Specific gene therapy for hereditary retinal dystrophies - an update].
Stieger K; Lorenz B
Klin Monbl Augenheilkd; 2014 Mar; 231(3):210-5. PubMed ID: 24327302
[TBL] [Abstract][Full Text] [Related]
9. Voretigene Neparvovec: A Review in RPE65 Mutation-Associated Inherited Retinal Dystrophy.
Kang C; Scott LJ
Mol Diagn Ther; 2020 Aug; 24(4):487-495. PubMed ID: 32535767
[TBL] [Abstract][Full Text] [Related]
10. Clinical Trials in Retinal Dystrophies.
Grob SR; Finn A; Papakostas TD; Eliott D
Middle East Afr J Ophthalmol; 2016; 23(1):49-59. PubMed ID: 26957839
[TBL] [Abstract][Full Text] [Related]
11. Navigating the current landscape of clinical genetic testing for inherited retinal dystrophies.
Lee K; Garg S
Genet Med; 2015 Apr; 17(4):245-52. PubMed ID: 25790163
[TBL] [Abstract][Full Text] [Related]
12. Gene Therapy in Retinal Dystrophies.
Ziccardi L; Cordeddu V; Gaddini L; Matteucci A; Parravano M; Malchiodi-Albedi F; Varano M
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31739639
[TBL] [Abstract][Full Text] [Related]
13. [Gene therapy for retinal dystrophies].
Charbel Issa P; Groppe M; MacLaren RE
Ophthalmologe; 2012 Feb; 109(2):121-8. PubMed ID: 22350548
[TBL] [Abstract][Full Text] [Related]
14. Frequency of
Kahraman NS; Öner A; Özkul Y; Dündar M
Turk J Ophthalmol; 2022 Aug; 52(4):270-275. PubMed ID: 36017377
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials.
Maguire AM; Russell S; Wellman JA; Chung DC; Yu ZF; Tillman A; Wittes J; Pappas J; Elci O; Marshall KA; McCague S; Reichert H; Davis M; Simonelli F; Leroy BP; Wright JF; High KA; Bennett J
Ophthalmology; 2019 Sep; 126(9):1273-1285. PubMed ID: 31443789
[TBL] [Abstract][Full Text] [Related]
16. [Gene therapy for hereditary eye diseases].
Kessel L; Bertelsen M; Klemp K; Christensen UC
Ugeskr Laeger; 2022 Nov; 184(45):. PubMed ID: 36345897
[TBL] [Abstract][Full Text] [Related]
17. Voretigene neparvovec-rzyl (Luxturna) for inherited retinal dystrophy.
Med Lett Drugs Ther; 2018 Mar; 60(1543):53-55. PubMed ID: 29635265
[No Abstract] [Full Text] [Related]
18. Dog models for blinding inherited retinal dystrophies.
Petersen-Jones SM; Komáromy AM
Hum Gene Ther Clin Dev; 2015 Mar; 26(1):15-26. PubMed ID: 25671556
[TBL] [Abstract][Full Text] [Related]
19. Lessons Learned from the Development of the First FDA-Approved Gene Therapy Drug, Voretigene Neparvovec-rzyl.
Bennett J; Maguire AM
Cold Spring Harb Perspect Med; 2023 May; 13(5):. PubMed ID: 36167727
[TBL] [Abstract][Full Text] [Related]
20. [Gene therapy for inherited retinal dystrophies].
Côco M; Han SW; Sallum JM
Arq Bras Oftalmol; 2009; 72(4):560-6. PubMed ID: 19820803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
